Yahoo Web Search

Search results

1. • 

     ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review

     Zacks via Yahoo Finance· 2 years ago

     ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead...

2. • 

     Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal

     Zacks via Yahoo Finance· 9 months ago

     Seagen Inc. SGEN announced positive top-line results from its late-stage HER2CLIMB-02 study,...

3. • 

     ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates

     Zacks via Yahoo Finance· 2 years ago

     ImmunoGen, Inc. IMGN incurred a loss of 24 cents per share for second-quarter 2022, wider than the...

4. • 

     Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat

     Zacks via Yahoo Finance· 2 years ago

     Shares of Puma Biotechnology PBYI were up 17.4% at market close on Aug 5, following the earnings...

5. • 

     An Important History Lesson for Gene-Editing Investors

     Motley Fool· 6 months ago

     The history of biotechnology is full of examples of promising technologies that took decades to...

6. • 

     Seagen Inc. (SGEN) Q3 2022 Earnings Call Transcript

     Motley Fool· 2 years ago

     Speakers on today's call will be Roger Dansey, interim chief executive officer and chief medical officer; Todd Simpson, chief financial officer; and Chip...

7. • 

     Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales

     Zacks via Yahoo Finance· 4 weeks ago

     Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue...

8. • Why Gilead Sciences Stock Was a 5% Winner Today

     Motley Fool· 2 years ago

     Gilead Sciences (NASDAQ: GILD) stock was off to a good start this week, rising by more than 5% on Monday against the modest (0.4%) gain of the S&P 500 index. The prominent pharmaceutical company ...

9. • 

     Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down

     Zacks via Yahoo Finance· 4 months ago

     Roche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in...